University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles

Simple item page
dc.contributor.authorRoberts, Sophie E.
dc.contributor.authorMartin, Heather L.
dc.contributor.authorAl-Qallaf, Danah
dc.contributor.authorTang, Anna A.
dc.contributor.authorTiede, Christian
dc.contributor.authorGaule, Thembaninkosi G.
dc.contributor.authorDobon-Alonso, Albor
dc.contributor.authorOverman, Ross
dc.contributor.authorShah, Sachin
dc.contributor.authorPeyret, Hadrien
dc.contributor.authorSaunders, Keith
dc.contributor.authorBon, Robin
dc.contributor.authorManfield, Iain W.
dc.contributor.authorBell, Sandra M.
dc.contributor.authorLomonossoff, George P.
dc.contributor.authorSpeirs, Valerie
dc.contributor.authorTomlinson, Darren C.
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.date.accessioned2024-08-19T11:57:01Z
dc.date.available2024-08-19T11:57:01Z
dc.date.issued2024-08-16
dc.descriptionWe thank Dr Rachel George of the Mass Spectrometry Facility at the University of Leeds for her technical assistance and the Horticultural and Bioimaging at the John Innes Centre for their support. HER2 Affimer screening was performed by D.C.T. D.A.Q. A.A.T. and C.T. Affimer characterization including Affimer-MMAE conjugates was carried out by S.E.R. S.P.R. was performed by S.E.R. and I.W.M. VLPs were produced by A.D.A. R.O. S.S. H.P. and K.S. Assessment of Affimer-VLP uptake was performed by H.L.M. and A.A.T. AlphaFold2 modeling was undertaken by T.G.G. S.E.R. H.L.M. R.O. S.M.B. G.P.L. V.S. and and D.C.T. designed the experiments in this manuscript. The manuscript was written by S.E.R. and H.L.M. All authors read and approved the final manuscript. The authors declare a potential conflict of interest. A patent application has been filed related to the work described in this manuscript. [Application number: LU505126, Inventors: George P. Lomonossoff, Sachin Shah, Keith Saunders, Darren C Tomlinson, Christian Tiede, Heather Martin, Ross Overman]. D.C.T. also is a named inventor on patent \u201Cscaffold protein derived from plant cystatins\u201D Europe 14705565.1, US 14/768,032, Australia 2014217628. G.P.L. also sits as a chair on the advisory board for Leaf Expression Systems.en
dc.description.statusPeer revieweden
dc.format.extent18
dc.format.extent6247569
dc.identifier292165520
dc.identifieraf2133fd-300a-463f-a32c-f76d972c42d9
dc.identifier85198578863
dc.identifier39104409
dc.identifier.citationRoberts, S E, Martin, H L, Al-Qallaf, D, Tang, A A, Tiede, C, Gaule, T G, Dobon-Alonso, A, Overman, R, Shah, S, Peyret, H, Saunders, K, Bon, R, Manfield, I W, Bell, S M, Lomonossoff, G P, Speirs, V & Tomlinson, D C 2024, 'Affimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particles', iScience, vol. 27, no. 8, 110461. https://doi.org/10.1016/j.isci.2024.110461en
dc.identifier.doi10.1016/j.isci.2024.110461
dc.identifier.iss8en
dc.identifier.issn2589-0042
dc.identifier.otherORCID: /0000-0002-0602-4666/work/165791614
dc.identifier.urihttps://hdl.handle.net/2164/24054
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85198578863&partnerID=8YFLogxKen
dc.identifier.vol27en
dc.language.isoeng
dc.relation.ispartofiScienceen
dc.subjectSubstantive connection via eligible employment contracten
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectR Medicine (General)en
dc.subjectGeneralen
dc.subjectSupplementary Informationen
dc.subjecthttps://ars.els-cdn.com/content/image/1-s2.0-S2589004224016869-mmc1.pdfen
dc.subject.lccR1en
dc.titleAffimer reagents enable targeted delivery of therapeutic agents and RNA via virus-like particlesen
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Roberts_etal_i_Affimer_reagents_enable_VOR.pdf
Size:
5.96 MB
Format:
Adobe Portable Document Format
Download

Collections

All research